Frontlight ResearchEarly access
Psoriatic arthritis trials in Canada
8 of 11 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 1SuspendedTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Where
- Toronto
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT03816345 - Phase 2Taking peopleStudy of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
- Where
- Saskatoon, Sherbrooke, Trois-Rivières
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- AbbVie
See details and how to joinNCT06865105 - Phase 3Taking peopleAn Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
- Where
- Calgary, Montreal, Saskatoon
- Age
- 2 years to 18 years
- People
- 40 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06668181 · EU 2023-508845-41-00 - No phaseTaking peopleModifying PEST for Psoriatic Arthritis Screening
- Where
- Barrie, Calgary, Edmonton, Fredericton, Greater Sudbury, Hamilton, Kelowna, London, Markham, Montreal, Ottawa, Québec, Richmond Hill, Saskatoon, Ste-Foy, Stoney Creek, Surrey, Toronto, Verdun, Waterloo, Winnipeg
- Age
- 18 years and over
- People
- 502
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06382051 - Phase 1Taking peopleA Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
- Where
- Calgary, Vancouver
- Age
- 18 years and over
- People
- 20 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06888193 · EU 2024-518689-29-00 - Phase 3Taking peopleA Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
- Where
- Calgary, Toronto, Vancouver
- Age
- 5 years to 17 years
- People
- 40 worldwide
- Run by
- AbbVie
See details and how to joinNCT06100744 · EU 2023-506026-36-00 - Phase 4Taking peopleA Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
- Where
- Ottawa, Québec
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- CARE ARTHRITIS LTD.
See details and how to joinNCT06454188 · EU 2023-510242-24-00 - No phaseNot yet taking people in CanadaPersonalized Outreach for Equitable Treatment in Rheumatology
- Where
- Vancouver
- Age
- 18 years and over
- People
- 20
- Run by
- University of British Columbia
See details and how to joinNCT07022756